474707-30-7

Basic information

• Product Name: (R)-3-METHOXY-PYRROLIDINE HYDROCHLORIDE
• Synonyms: (3R)-3-METHOXYPYRROLIDINE HYDROCHLORIDE;(R)-3-METHOXY-PYRROLIDINE HYDROCHLORIDE;(R)-3-Methoxypyrrolidine HCl
• CAS NO: 474707-30-7
• Molecular Formula: C₅H₁₁NO*ClH
• Molecular Weight: 137.609
• Mol File: 474707-30-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: (R)-3-METHOXY-PYRROLIDINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-METHOXY-PYRROLIDINE HYDROCHLORIDE(474707-30-7)
• EPA Substance Registry System: (R)-3-METHOXY-PYRROLIDINE HYDROCHLORIDE(474707-30-7)

Safety Data

• Hazardous Substances Data: 474707-30-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-3-METHOXY-PYRROLIDINE HYDROCHLORIDE is used as a chiral building block for the synthesis of various pharmaceuticals and organic compounds. Its chiral nature allows for the creation of enantiomerically pure compounds, which are essential in the development of drugs with specific therapeutic effects and reduced side effects.
Used in Organic Synthesis:
(R)-3-METHOXY-PYRROLIDINE HYDROCHLORIDE is used as a versatile intermediate in the synthesis of a wide range of organic compounds. Its unique structure and reactivity make it a valuable component in the preparation of complex organic molecules, including natural products, agrochemicals, and other specialty chemicals.
Used in Research and Development:
(R)-3-METHOXY-PYRROLIDINE HYDROCHLORIDE is utilized as a key compound in research and development efforts aimed at understanding the role of chirality in chemical reactions and biological systems. Its unique properties and structure provide valuable insights into the mechanisms of enantioselective synthesis and the development of novel chiral catalysts and reagents.

InChI:InChI=1/C5H11NO.ClH/c1-7-5-2-3-6-4-5;/h5-6H,2-4H2,1H3;1H/t5-;/m1./s1

Upstream product

• 549532-08-3 3R-methoxypyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1334829-84-3 2-[(3R)-3-methoxypyrrolidin-1-yl]ethanol 
• 1443992-94-6 (R)-3-methoxy-1-((S)-1-(trityloxy)propan-2-yl)pyrrolidine 

Relevant articles and documents

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY

This invention relates to compounds of formula (I).

PYRAZOLO`4,3-D! PYRIMIDINES

This invention relates to compounds of formula (I).

PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.

TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA

A compound of formula (I), a pharmaceutically acceptable salt or solvate thereof, wherein R' represents C,-C6 alkyl,-(CH2)c-[C3-C8 cycloalkyl]-,-(CH2)C-W or-(CH2)C-Z-(CH2)dW; W represents C1-C6 alkyl, C1-C6 alkyloxy,-C02[C1-C6 alkyl],-CONR4R5, an optionally substituted phenyl group, NR4R5, het2 or het3; Z represents O or S(O)g; g represents 0, 1 or 2; R2 represents a phenyl group, optionally fused to a 5-or 6-membered aryl or heterocyclic group which may contain one or more heteroatoms selected from N, O or S; the phenyl group and the optionally fused group being optionally substituted; Ring A represents a 4-, 5-or 6-membered saturated heterocyclic group containing at least one N; Ring B represents a phenyl group or het1, each group being optionally substituted; R7 independently represents H1 C1-C6alkyl, OR3,-(CH2)e-R3 or-(CH2)f-O-(CH2)e-R3; at each occurrence R3 independently represents H1 C1-C6 alkyl optionally substituted by Y,-(CH2)g [C3-C8 cycloalkyl], phenyl, benzyl, pyridyl or pyrimidyl; at each occurrence R4 and R5independently represent H1 Cl-C6 alkyl (optionally substituted with Cl-C6alkyloxy), (CH2)gC02-[C1-C6 alkyl],-S02Me,-(CH2)g[C3-C8 cycloalkyl], S02Me, phenyl, benzyl, pyridyl or pyrimidyl; or R4 and R5 together with the N atom to which they are attached represent a heterocyclic group of from 3 to 8 atoms; Y independently represents a phenyl group, NR4R5 or het4, the phenyl group being optionally substituted; het1 represents a 4-, 5-or 6-membered saturated, or unsaturated, heterocyclic group containing at least one N (but which may also contain one or more O or S atoms); het2 and het4 represent an optionally substituted 4-, 5-, 6-or 7-membered saturated, or unsaturated, heterocyclic group containing at least one N (but which may 5 also contain one or more O or S atoms); het3 represents an optionally substituted 4-, 5-, 6-or 7-membered saturated, or unsaturated, heterocyclic group containing at least one O (but which may also contain one or mare N or S atoms); at each occurrence R6 independently represents H1 C1-C6 alkyl optionally substituted by Y, =(CH2)g [C3-C8 cycloalkyl], phenyl, benzyl, pyridyl or pyrimidyl; a and b independently represent 0 or 1; c,, d, a end g independently represent 0, 1, 2, 3 or 4; . f índeperldently represents 1, 2, 3 or 4; provided that: (i) a + b cannot equal 0; and províded,that,when R1 represents-(CH2)c-Z-(CH2)d-W and W represents.NR4R5 or any N linked heterocyclic, group then d must not be, 0 or 1; and (iii), provided that when R2 represents a phenyl group substituted by a group of, formula-(CH2)eOR3,-(CH2)e-OCOR3 or-(CH2)e,OCOR3 ;or het1,and/or het2 are substituted by a group of formula-(CH2)eOR3, (CH2),-CO2R3 or-(CH2)eOCOR3; or when R7 represents-OR3 or-(CH2)f-0-(CH2)e-R3 and e is 0; or when W represents a phenyl group substituted with-OR3 or-C02R3 and R3 represents an alkyl group substituted with Y, and Y represents NR4R5 or an N-Finked het3; then, R3, must,represent,C2-C6 alkyl substituted with. Y. are useful in the treatment of dysmenorrhoea.